Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04369950
Other study ID # HSC-MS-19-0951
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 11, 2020
Est. completion date July 11, 2021

Study information

Verified date April 2022
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to show that the effect of 3% 2-chloroprocaine prior to epidural morphine administration will be not inferior to the effect of epidural 2% lidocaine with 1:200,000 epinephrine on total opioid use for 24h


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date July 11, 2021
Est. primary completion date May 11, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - pregnant patients - live singleton pregnancy Exclusion Criteria: - BMI >40 - obstructive sleep apnea - drug abuse - chronic pain - chronic opioid use - nonfunctioning epidural

Study Design


Intervention

Drug:
2% lidocaine with 1:200,000 epinephrine and epidural morphine
Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
3% 2-chloroprocaine and epidural morphine
Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Amount of Opioid Used 24 hours after epidural morphine administration
Secondary Total Amount of Opioid Used 12 hours after epidural morphine administration
Secondary Total Amount of Opioid Used 8 hours after epidural morphine administration
Secondary Total Amount of Opioid Used 4 hours after epidural morphine administration
Secondary Pain as Measured by a 11 Point Verbal Scale scale ranges form 0-10, higher number indicating more pain 4,8, 12 and 24 hours after epidural morphine administration
Secondary Number of Participants Who Had Mild, Moderate or Severe Nausea as Measured by a 3 Point Scale scale ranges from non,mild and moderate-severe 4,8, 12 and 24 hours after epidural morphine administration
Secondary Number of Participants Who Had Mild, Moderate or Severe Pruritis as Measured by a 3 Point Scale scale ranges from non,mild and moderate-severe 4,8, 12 and 24 hours after epidural morphine administration
Secondary Time Until First Opioid Request Up to 48 hours after epidural morphine administration
See also
  Status Clinical Trial Phase
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05089526 - Opioid-free Anesthesia in Laparoscopic Cholecystectomies N/A
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Completed NCT03761433 - Intraoperative Nociception and Postoperative Pain
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT05717361 - Opioid Sparing Anesthesia in Cervical Spine Surgery N/A
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT04254081 - Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion Phase 4
Recruiting NCT03655847 - Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection Phase 4
Completed NCT02085577 - The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients Phase 4
Completed NCT01387750 - Mentholated Cream Containing Oxygenated Glycerol Triesters on Acute Pain of the Muscles and Joints Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04309084 - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Phase 1
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Enrolling by invitation NCT06402149 - Comparison of 2 Different Methods in Infraclavicular Block
Completed NCT03585088 - The Prediction for Postoperative Pain N/A
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Completed NCT02046681 - Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65 N/A
Recruiting NCT06274814 - U/S Guided Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block vs Type 2 Pectoral Nerve Block N/A